Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Viral hepatitis

Drug–drug interactions in HCV treatment — the good, the bad and the ugly

Nature Reviews Gastroenterology & Hepatology volume 13, pages 194–195 (2016)Cite this article

Subjects

A recent study demonstrated that drug–drug interactions are common in patients with HCV and are a challenge for treatment. Identification of these interactions can be time-consuming and complex. A multidisciplinary approach to HCV treatment, including a clinical pharmacist, can help identify and manage HCV drug interactions.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Höner Zu Siederdissen, C. et al. Drug–drug interactions with novel all-oral interferon-free antiviral agents in a large real-world cohort. Clin. Infect. Dis. http://dx.doi.org/10.1093/cid/civ973 (2015).

  2. Badri, P. S. et al. Dosing recommendations for concomitant medication during 3D anti-HCV therapy. Clin. Pharmacokinet. http://dx.doi.org/10.1007/s40262-015-0317-8 (2015).

  3. Reddy, M. B. et al. Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin. Pharmacokinet. 51, 457–465 (2012).

    Article  CAS  Google Scholar 

  4. El-Sherif, O., Khoo, S. & Solas, C. Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection. Curr. Opin. HIV AIDS 10, 348–354 (2015).

    Article  CAS  Google Scholar 

  5. Lauffenburger, J. C. et al. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential. Eur. J. Gastroenterol. Hepatol. 26, 1073–1082 (2014).

    Article  CAS  Google Scholar 

  6. Vassalle, C., Masini, S., Bianchi, F. & Zucchelli, G. C. Evidence for association between hepatitis C virus seropositivity and coronary artery disease. Heart 90, 565–566 (2004).

    Article  CAS  Google Scholar 

  7. Petta, S., Macaluso, F. S. & Craxì, A. Cardiovascular diseases and HCV infection: a simple association or more? Gut 63, 369–375 (2014).

    Article  Google Scholar 

  8. Renet, S. et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 149, 1378–1380 (2015).

    Article  CAS  Google Scholar 

  9. Back, D. J. & Burger, D. M. Interaction begtween amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 149, 1315–1317 (2015).

    Article  Google Scholar 

  10. Seeff, L. B. et al. Herbal products use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47, 605–612 (2008).

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Gregory T. Everson is at the University of Colorado Denver, Department of Medicine, Division of Gastroenterology and Hepatology, Aurora, Colorado 80045, USA.

Authors and Affiliations

  1. Jacob A. Langness is at the University of Colorado Hospital and the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA.,

    Jacob A. Langness & Gregory T. Everson

Authors
  1. Jacob A. Langness
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory T. Everson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob A. Langness.

Ethics declarations

Competing interests

G.T.E. is on the advisory boards for Abbvie, Abbvie-Abbott, Bristol-Myers Squibb, Eisai, Gilead, GlobeImmune, Human Genome Sciences-Novartis, Janssen-Tibotec, Pfizer, Roche-Genentech and Vertex. He acts as a Consultant for Abbvie, Biotest, Boehringer-Ingelheim, Bristol-Myers Squibb, Human Genome Sciences-Novartis, Roche-Genentech, Three Rivers-Kadmon and Vertex. He is on the Data and Safety Monitoring Board for Centocor, Galectin and Merck. He has Stock/Ownership in HepQuant LLC and is involved in the management of HepQuant LLC. He also has Research Grants from Abbvie, Bristol-Myers Squibb, Eisai, Gilead, GlaxoSmithKline, GlobeImmune, Human Genome Sciences-Novartis, Janssen-Tibotec, Ortho Biotech, Pfizer, Pharmassett, Roche-Genentech, Schering-Merck, Source and Vertex. J.A.L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Langness, J., Everson, G. Drug–drug interactions in HCV treatment — the good, the bad and the ugly. Nat Rev Gastroenterol Hepatol 13, 194–195 (2016). https://doi.org/10.1038/nrgastro.2016.24

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2016.24

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing